Analytical Data
-
基因名
ST3GAL4
- Application
-
别名
ST3GAL4; CGS23; NANTA3; SIAT4C; STZ; CMP-N-acetylneuraminate-beta-galactosamide-alpha-2.3-sialyltransferase 4; Alpha 2.3-ST 4; Beta-galactoside alpha-2.3-sialyltransferase 4; EC 2.4.99.2; EC 2.4.99.4; Alpha 2.3-sialyltransferase IV; Gal-NAc6S; Gal-beta-1.4-GalNAc-alpha-2.3-sialyltransferase; SAT-3; ST-4; ST3Gal IV; ST3GalIV; ST3GalA.2; STZ; Sialyltransferase 4C; SIAT4-C
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q11206
-
表达区间
31-130 aa
-
氨基酸序列
FYFPIPEKKEPCLQGEAESKASKLFGNYSRDQPIFLRLEDYFWVKTPSAYELPYGTKGSEDLLLRVLAITSSSIPKNIQSLRCRRCVVVGNGHRLRNSSL
-
分子量
36.74 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ST3GAL4, a member of the ST3Gal family of sialyltransferases, plays a crucial role in the biosynthesis of glycoproteins and glycolipids by adding sialic acid to terminal galactose residues. This enzymatic activity is vital for various cellular processes, including cell-cell interactions, immune response modulation, and the maintenance of protein stability. Dysregulation of ST3GAL4 has been implicated in several diseases, notably cancer, where alterations in sialylation patterns can promote tumor progression and metastasis. Research on ST3GAL4 recombinant protein has gained significant attention as scientists aim to understand its functional mechanisms and explore its potential as a therapeutic target. Using recombinant DNA technology, researchers can produce ST3GAL4 in a controlled environment, allowing for detailed analysis of its enzymatic properties, substrate specificity, and the impact of its activity on cellular behavior. Such studies not only enhance our comprehension of sialylation biology but also pave the way for developing novel treatments for sialic acid-related disorders. By elucidating the role of ST3GAL4 in pathophysiological contexts, researchers hope to uncover new diagnostic markers and therapeutic avenues, contributing to advancements in precision medicine. Thus, the investigation of ST3GAL4 recombinant protein is a critical endeavor in understanding the complexities of glycosylation and its implications in health and disease.
